Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

167499

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	fpa
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much funding the Family Planning Association has received from the Government in each of the last four years; and what funding will be made available to the Family Planning Association.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	216877
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>In each of the last four years the Family Planning Association (FPA) has received:</p><p> </p><p> </p><p> </p><p>- 2011-12: £1,376,000</p><p> </p><p>- 2012-13: £571,797</p><p> </p><p>- 2013-14: £390,713</p><p> </p><p>- 2014-15: £239,365 (with a further £111,818 due to be invoiced by 31 March 2015)</p><p> </p><p>Discussions are continuing with the FPA about extending their contract for a year in 2015-16.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 05/12/2014 14:10:44 answering member 3918 label Biography information for Jane Ellison
	tabling member	4036 label Biography information for Luciana Berger

167497

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Terrence Higgins Trust
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 1 December 2014, Official Report, columns 1107-19HL, by how much the funding for the Terrence Higgins Trust will be reduced.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	216947
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>Discussions are continuing with Terrence Higgins Trust about extending their contract for a year in 2015-16.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 05/12/2014 14:11:48 answering member 3918 label Biography information for Jane Ellison
	tabling member	4036 label Biography information for Luciana Berger

167510

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Speech and Language Therapy: Warrington
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many qualified speech and language therapists have been employed by the NHS in Warrington in each year since 2009-10.
	tabling member constituency	Warrington North
	tabling member printed	Helen Jones
	uin	216816
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The information requested is shown in the attached table.</p><p> </p><p> </p><p><br></p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 05/12/2014 12:59:48 answering member 3932 label Biography information for Dr Dan Poulter attachment 1 file name Speech and Language Therapists Warrington 216816.docx title Speech and Language Therapists Warrington
	tabling member	432 label Biography information for Helen Jones

167513

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sleeping Pills
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent representations he has received on the prescription of zolpidem.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	216755
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>In the 6 month period, June 2014 to November 2014, the Department received no written representations concerning the prescribing of zolpidem (Stilnoct).</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 12:50:25 answering member 4020 label Biography information for George Freeman
	tabling member	4131 label Biography information for Jim Shannon

167511

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Peterborough and Stamford Hospitals NHS Foundation Trust
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many (a) elective and (b) non-elective operations were carried out in the Peterborough and Stamford Hospitals NHS Foundation Trust in each year since 2004.
	tabling member constituency	Peterborough
	tabling member printed	Mr Stewart Jackson
	uin	216831
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p><strong> </strong></p><p> </p><p>Information is not available in the format requested.</p><p> </p><p> </p><p> </p><p>Information on the number of Finished Consultant Episodes (FCE) for all main procedures by admission method carried out in the Peterborough and Stamford Hospitals NHS Foundation Trust in each year since 2003-04 is shown in the table below:</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Elective Admission Method</p></td><td><p>Non-Elective Admission Method</p></td><td><p>Other Admission Method</p></td></tr><tr><td><p>2003-04</p></td><td><p>28,587</p></td><td><p>6,803</p></td><td><p>4,037</p></td></tr><tr><td><p>2004-05</p></td><td><p>29,488</p></td><td><p>7,567</p></td><td><p>4,057</p></td></tr><tr><td><p>2005-06</p></td><td><p>30,690</p></td><td><p>7,403</p></td><td><p>3,961</p></td></tr><tr><td><p>2006-07</p></td><td><p>29,868</p></td><td><p>8,902</p></td><td><p>4,274</p></td></tr><tr><td><p>2007-08</p></td><td><p>34,699</p></td><td><p>9,803</p></td><td><p>5,389</p></td></tr><tr><td><p>2008-09</p></td><td><p>34,425</p></td><td><p>10,545</p></td><td><p>4,674</p></td></tr><tr><td><p>2009-10</p></td><td><p>36,015</p></td><td><p>12,674</p></td><td><p>4,833</p></td></tr><tr><td><p>2010-11</p></td><td><p>36,581</p></td><td><p>13,431</p></td><td><p>5,230</p></td></tr><tr><td><p>2011-12</p></td><td><p>38,706</p></td><td><p>14,299</p></td><td><p>5,390</p></td></tr><tr><td><p>2012-13</p></td><td><p>39,681</p></td><td><p>13,957</p></td><td><p>5,607</p></td></tr></tbody></table><p> </p><p><em>Source: </em>Health and Social Care Information Centre, Hospital Episode Statistics (HES)</p><p> </p><p><strong> </strong></p><p> </p><p><em>Note: </em></p><p> </p><ol start="1" type="1"><li>A FCE is a continuous period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which they end. Figures do not represent the number of different patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</li><li>The main procedure is the first recorded procedure or intervention in each episode, usually the most resource intensive procedure or intervention performed during the episode. It is appropriate to use main procedure when looking at admission details, (e.g. time waited), but a more complete count of episodes with a particular procedure is obtained by looking at the main and the secondary procedures.</li></ol><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 05/12/2014 14:13:30 answering member 3918 label Biography information for Jane Ellison
	tabling member	1551 label Biography information for Lord Jackson of Peterborough

166622

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the proposed re-evaluation of treatments on the Cancer Drugs Fund list, what assurances they can provide to patients with pancreatic cancer that the latest medicines will continue to be made available to them on the National Health Service.
	tabling member printed	Baroness Masham of Ilton
	uin	HL3213
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.</p><p> </p><p><br> NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br> We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p><br> NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:28:28 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton

166623

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure that all treatments for advanced pancreatic cancer shown to be effective are made available to patients on the National Health Service.
	tabling member printed	Baroness Masham of Ilton
	uin	HL3214
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.</p><p> </p><p><br> NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br> We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p><br> NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:29:26 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton

166758

	registered interest
	date	28/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on the need to recognise levels of unmet need in pancreatic cancer when re-evaluating treatments on the Cancer Drugs Fund.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	216451
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>We have had no such discussions. These are matters for NHS England’s Cancer Drugs Fund clinical panel.</p><p> </p><p> </p><p> </p><p>The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>In making such decisions, the panel will take into account a number of factors, including unmet need.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 14:19:34 answering member 4020 label Biography information for George Freeman
	tabling member	1538 label Biography information for Rosie Cooper

167516

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Organs: Donors
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that donated organs are suitable for transplant.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	216752
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>Potential donors are screened for a number of infections, such as HIV, Hepatitis B and C, Syphilis, Cytomegalovirus and Human T-cell lymphotropic virus. In addition, organs are routinely evaluated prior to retrieval, during retrieval and before implantation by both the retrieval team and the transplantation clinical team.</p><p> </p><p>Trained Specialist Nurses in Organ Donation review the donor’s clinical notes and contact the general practitioner or relevant health professional to obtain the medical history. In order to build an accurate background of the donor’s social and medical history, the Specialist Nurse approaches the family to gather information about the potential donor’s lifestyle choices, travel history and other factors that may impact on whether or not a donor’s organs are appropriate for transplantation, using a standard form to ensure that all relevant history is captured. The decision whether or not to accept an organ for a patient is ultimately made by the transplant surgeon, using their clinical expertise and the information collected to carefully weigh up the risks.</p><p> </p><p>In line with guidance, the transplant team discuss with the potential recipient any known risks associated with the organ which could affect its function in the short and long term before obtaining consent for its use.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 05/12/2014 13:07:31 answering member 3918 label Biography information for Jane Ellison
	tabling member	4131 label Biography information for Jim Shannon

167505

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nalmefene
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what guidance his Department issues on whether local authorities or clinical commissioning groups should fund the cost of the drug Nalmefene.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	216875
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance on 26 November which recommends nalmefene (Selincro) as a possible treatment for people with alcohol dependence, subject to certain criteria.</p><p> </p><p> </p><p> </p><p>NHS commissioners and local authorities, with respect to their public health functions, are legally required to make funding available for treatments recommended by NICE technology appraisal guidance, within three months of NICE’s final guidance.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 13:14:18 answering member 4020 label Biography information for George Freeman
	tabling member	4036 label Biography information for Luciana Berger